ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer americanpharmaceuticalreview
May 24, 2021On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received ... -
EMA launches review of BMS’ Opdivo for oesophageal cancer pharmatimes
January 06, 2021The European Medicines Agency (EMA) has launched its centralized review process for Bristol Myers Squibb’s Opdivo (nivolumab) as an adjuvant treatment for oesophageal or gastroesophageal junction (GEJ) cancer. -
Bristol Myers Squibb’s Opdivo shows benefit in oesophageal cancers pharmatimes
September 23, 2020Bristol Myers Squibb’s Opdivo (nivolumab) demonstrated promise in a phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction (GEJ) cancers who had previously receiving neoadjuvant chemoradiation therapy (CRT) and ...
Pharma Sources Insight January 2025
